期刊文献+

配对相关同源框1蛋白、癌易感性候选基因2在原发性肝癌组织中的表达及临床意义

Expression and clinical significance of paired related homoeobox-1 and cancer susceptibility candidate-2 in primary hepatic carcinoma
下载PDF
导出
摘要 目的:分析配对相关同源框1蛋白(paired related homoeobox-1,PRRX1)、癌易感性候选基因2(cancer susceptibility candidate-2,CASC2)在原发性肝癌组织的表达特点,探讨其与临床病理参数和预后的关系。方法:收集2014年1月至2017年1月收治的72例经手术切除的原发性肝癌患者癌组织、癌旁组织石蜡标本。采用实时荧光定量聚合链反应(real-time fluorescence quantitative polymerization chain reaction,qRT-PCR)检测PRRX1、CASC2表达。分析PRRX1、CASC2表达与临床病理参数的关系。以随访期间患者死亡为终点事件,分析PRRX1、CASC2表达与患者预后的关系。结果:原发性肝癌组织中PRRX1、CASC2表达均低于癌旁组织(P<0.05)。PRRX1表达与血管侵犯、肝内转移、远端转移和TNM分期有关系(P<0.05);CASC2表达与肿瘤分化程度、TNM分期有关系(P<0.05)。Kaplan-Meier生存曲线分析结果显示,PRRX1低表达组、CASC2低表达组原发性肝癌患者3年生存率均低于PRRX1高表达组、CASC2高表达组患者(P<0.05)。多因素Cox回归分析结果显示,远端转移、PRRX1低表达、CASC2低表达与原发性肝癌患者不良预后独立相关(P<0.01)。结论:PRRX1、CASC2在原发性肝癌组织中呈低表达。PRRX1、CASC2低表达可能与原发性肝癌发生和进展有关,可作为其预后评估的辅助指标。 Objective:To investigate the expression of paired related homoeobox-1(PRRX1)and cancer susceptibility candidate-2(CASC2)in primary hepatic carcinoma,and analyze their relationship with clinicopathological parameters and prognosis.Methods:Paraffin specimens were collected from 72 patients with primary hepatic carcinoma from January 2014 to January 2017.The expressions of PRRX1 and CASC2 were detected by real-time fluorescence quantitative polymerization chain reaction(qRT-PCR),and the relationship between the expressions of PRRX1 and CASC2 and the clinicopathological parameters of primary hepatic carcinoma was analyzed.The relationship between the expression of PRRX1 and CASC2 and the prognosis of primary hepatic carcinoma patients was analyzed with death of primary hepatic carcinoma patients as the endpoint event during follow-up.Results:The expression of PRRX1 and CASC2 in primary hepatic carcinoma tissues was lower than that in paracarcinoma tissues(P<0.05).The expression of PRRX1 was associated with vascular invasion,intrahepatic metastasis,distal metastasis and TNM stage(P<0.05).The expression of CASC2 was associated with the degree of differentiation and TNM stage(P<0.05).The results of Kaplan-Meier survival curve analysis showed that the survival rate of primary hepatic carcinoma in the low-expression group of PRRX1 and CASC2 was lower than that in the high-expression group of PRRX1 and CASC2(P<0.05).Multivariate Cox regression analysis showed that distal metastasis,low expression of PRRX1 and CASC2 were independently correlated with poor prognosis of primary hepatic carcinoma patients(P<0.01).Conclusions:PRRX1 and CASC2 were under expressed in primary hepatic carcinoma.Low expression of PRRX1 and CASC2 in primary hepatic carcinoma may be related to the pathogenesis and malignant progression of primary hepatic carcinoma,which can be used as an auxiliary indicator for the prognosis assessment of primary hepatic carcinoma.
作者 李文超 张冬 张东霞 Li Wenchao;Zhang Dong;Zhang Dongxia(Department of Hepatology,Xingtai People's Hospital,Xingtai 054000,Hebei,China;Department of Hepatology,Tangshan People's Hospital,Tangshan 063000,Hebei,China;Department of Emergency,Xingtai People's Hospital,Xingtai 054000,Hebei,China)
出处 《肝癌电子杂志》 2021年第4期21-25,共5页 Electronic Journal of Liver Tumor
基金 河北省2020年度医学科学研究课题计划(20201536)。
关键词 配对相关同源框1蛋白 癌易感性候选基因2 原发性肝癌 Paired related homoeobox-1 proteins Cancer susceptibility candidate-2 Primary hepatic carcinoma
  • 相关文献

参考文献6

二级参考文献37

  • 1Minal Garg.Epithelial-mesenchymal transition- activating transcription factors- multifunctional regulators in cancer[J].World Journal of Stem Cells,2013,5(4):188-195. 被引量:26
  • 2Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, ZhangSL, Thike AA, Pandey A, Rozen S, Voorhoeve PM, Yu Q, TanPH, Bay BH, Itahana K, Tan P. TP53 genomic status regulatessensitivity of gastric cancer cells to the histone methylationinhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res 2012;18: 4201-4212 [PMID: 22675170 DOI: 10.1158/1078-0432.CCR-12-0036].
  • 3Buffart TE, Carvalho B, van Grieken NC, van Wieringen WN,Tijssen M, Kranenbarg EM, Verheul HM, Grabsch HI, Ylstra B,van de Velde CJ, Meijer GA. Losses of chromosome 5q and 14qare associated with favorable clinical outcome of patients withgastric cancer. Oncologist 2012; 17: 653-662 [PMID: 22531355DOI: 10.1634/theoncologist.2010-0379].
  • 4Xia JT, Chen LZ, Jian WH, Wang KB, Yang YZ, He WL, HeYL, Chen D, Li W. MicroRNA-362 induces cell proliferationand apoptosis resistance in gastric cancer by activation of NF-κB signaling. J Transl Med 2014; 12: 33 [PMID: 24495516 DOI:10.1186/1479-5876-12-33].
  • 5Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, Jin Y, Wu Y.miR-34a regulates cisplatin-induce gastric cancer cell death bymodulating PI3K/AKT/survivin pathway. Tumour Biol 2014; 35:1287-1295 [PMID: 24068565 DOI: 10.1007/s13277-013-1171-7].
  • 6Calin GA, Croce CM. MicroRNA signatures in human cancers.Nat Rev Cancer 2006; 6: 857-866 [PMID: 17060945 DOI:10.1038/nrc1997].
  • 7Wu Q, Yang Z, An Y, Hu H, Yin J, Zhang P, Nie Y, Wu K, Shi Y,Fan D. MiR-19a/b modulate the metastasis of gastric cancer cellsby targeting the tumour suppressor MXD1. Cell Death Dis 2014; 5:e1144 [PMID: 24675462 DOI: 10.1038/cddis.2014.110].
  • 8Pan HW, Li SC, Tsai KW. MicroRNA dysregulation in gastriccancer. Curr Pharm Des 2013; 19: 1273-1284 [PMID: 23092346DOI: 10.2174/138161213804805621].
  • 9Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, RossiS, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H,Nomura S, Seto Y, Kaminishi M, Calin GA, Croce CM. Relationbetween microRNA expression and progression and prognosisof gastric cancer: a microRNA expression analysis. LancetOncol 2010; 11: 136-146 [PMID: 20022810 DOI: 10.1016/S1470-2045(09)70343-2].
  • 10Wang F, Sun GP, Zou YF, Hao JQ, Zhong F, Ren WJ. MicroRNAsas promising biomarkers for gastric cancer. Cancer Biomark 2012;11: 259-267 [PMID: 23248184 DOI: 10.3233/CBM-2012-00284].

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部